Promising clinical trials against non-small cell lung cancer with Antroquinonol

The research against cancer has not ceased. The scientific community and big pharma continue to test medications with the hope of finding something that can prevent or cure this disease that causes suffering and death all over the world every year.

Some projects have been ineffective, but others have renewed our hope. For example, there have been some promising clinical trials against non-small cell lung cancer using Antroquinonol, extracted from a Taiwanese mushroom. Although more studies need to be done, there have been some significant discoveries.

About non-small cell lung cancer
Non-small cell lung cancer develops when lung tissue is filled with malignant cells. Cigarettes appear to be the primary risk factor of this disease, which manifests from loss of breath and constant coughing.

Three classes of lung cancer have been identified, depending on the type of cancer cells that form them: squamous cell carcinoma (from squamous cells), which manifest similarly to the scales of a fish, named for their plain and thin appearance; large cell carcinoma, formed by larger cells; and adenocarcinoma, which forms around the alveolus and produces a mucous-like substance.  

According to medical professionals, there is no existing treatment to cure this cancer in a majority of patients. However, after it is detected, the patient has the opportunity to participate in currently active clinical trials to improve the treatment of this pathology.

Clinical Trials with Antroquinonol
One of the clinical trials that currently stands out has to do with Antroquinonol, a natural extract from the mushroom Antrodia camphorata, which has been used in traditional Chinese medicine and one which Golden Biotechnology has studied in the name of human health.  

The research revealed promising results, as it was shown that it has antitumor effects against various types of cancer cells. Scientists are honing in on learning more about its specific effects in the treatment against non-small cell lung cancer.

Until now we know that Antroquinonol notably reduces the propagation of three cells that cause NSCLC. One treatment that uses this compound increases cellular contraction, the formation of pores, apoptotic vacuoles and the presence of positive cells. It has various effects:

-          Anti-proliferative effect on three types of cells that cause large cell carcinoma of the lung and adenocarcinoma. The proper dosage of this substance reduces the viability of the three cell lines.

-          Effect on the distribution of the cell cycle and the proteins in the cell cycle. Antroquinonol helps inhibit cellular growth and reduces the accumulation of some types of proteins.

-          Apoptotic effect on some cells. This implies an increase in the accumulation of apoptotic cells.

At the same time, this substance reduces the presence of negative proteins without altering the presence of favorable ones. Potential was observed in the mitochondrial membrane when it came to induced apoptosis. In the same way, it regulates the expression of some proteins, which influences the reduction of damaging substances.

After a series of studies and tests with descriptive results, it was suggested that Antroquinonol could become a chemotherapeutic agent for the treatment against non-small cell lung cancer because it has an anti-carcinogenic mechanism based on the myriad of data.

Although testing continues and there is still much more to investigate, the clinical trials using Antroquinonol have demonstrated favorable results in the treatment against non-small cell lung cancer, which until now has no cure.